A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 41 people enrolled
- Started
- 14 Nov 2022
- Ended
- 10 Jan 2024
- Type of study
- Interventional, 8 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- LY3875383
- Placebo
- Record updated
- 4 June 2025
- Why it stopped
- The study was terminated due to a change in risk/benefit ratio, which no longer favoured continued development.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- All participants:
- Have a body mass index (BMI) between 18.5 and 40 kilograms per square meter (kg/m²), inclusive
- Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP); Healthy participants (Part A):
- Participants must be overtly healthy, as determined by medical evaluation; For Part B:
- Participants must be first-generation Japanese, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan; Hypertriglyceridemia participants (Parts C and D):; For Part C:
- Have history of very high triglyceride (lipid) level 500 mg/dL ≤ TG <2000 mg/dL, which needs to be further confirmed at screening
- Participants must be on a lipid-modifying diet and can be on stable lipid-lowering drugs (LLDs) for at least 8 weeks before screening and plan to continue the same throughout the study duration; For Part D:
- Have history of high triglyceride (lipid) level between 150 mg/dL and 500 mg/dL inclusive at pre-screening or based on medical history and confirmed at screening and Low-density lipoprotein cholesterol (LDL-C) level of ≥40 mg/dL
- Participants must be on a stable moderate or high-intensity dose of a statin for at least 8 weeks before screening and plan to continue the same medication and dose throughout the study duration
Who cannot take part
- Have donated blood of more than 500 mL within the previous 3 months
- Have one of the following viral infections: hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV)
- All participants:
- Participants must not be currently participating in or completed a clinical trial within the last 30 days
- Participants must not be heavy alcohol drinkers or cigarette smokers; For Part C: Have active pancreatitis within the last 6 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.
The 8 groups in the trial
- LY3875383 (Part A)Treatment being tested
Single-ascending doses of LY3875383 administered subcutaneously (SC).
Treatment: LY3875383
- LY3875383 (Part B)Treatment being tested
Single doses of LY3875383 administered SC.
Treatment: LY3875383
- LY3875383 (Part C)Treatment being tested
Single doses of LY3875383 administered SC.
Treatment: LY3875383
- LY3875383 (Part D)Treatment being tested
Single doses of LY3875383 administered SC.
Treatment: LY3875383
- Placebo (Part A)Placebo, for comparison
Placebo administered SC.
Treatment: Placebo
- Placebo (Part B)Placebo, for comparison
Placebo administered SC.
Treatment: Placebo
- Placebo (Part C)Placebo, for comparison
Placebo administered SC.
Treatment: Placebo
- Placebo (Part D)Placebo, for comparison
Placebo administered SC.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
- Record updated
- 4 June 2025